bpv Huegel advised Valneva SE in its successful delisting from the Vienna Stock Exchange
bpv Huegel advised Valneva SE, headquartered in France, in the delisting of its
shares from the regulated market of the Vienna Stock Exchange. The delisting aims to centralise the trading of the shares on the Euronext Paris.
It was one of the first delistings in Austria under the new delisting regime of Section 38 of the Austrian Stock Exchange Act. Such delisting without the provision of a cash compensation may be executed in case of another listing on a regulated market (EEA member state) with equivalent delisting conditions.
Valneva SE is a biotech company developing and commercialising vaccines for infectious diseases with major unmet needs. Valneva SE’s portfolio includes two commercial vaccines for travellers: IXIARO®/JESPECT® indicated for the prevention of Japanese encephalitis and DUKORAL® indicated for the prevention of cholera and, in some countries, prevention of diarrhoea caused by ETEC. The Company has various vaccines in development including a unique vaccine against Lyme disease. Valneva SE has operations in Austria, Sweden, the United Kingdom, France, Canada and the US.
bpv Huegel`s team was led by Elke Napokoj (Partner, Capital Markets/M&A) and included Michaela Pelinka (Partner, Corporate) and David Pukel (Associate, Capital Markets/M&A).
bpv Huegel’s capital market team is regularly involved in high profile capital market transactions and already advised on the outbound cross-border merger between listed Intercell AG and listed Vivalis SA forming Valneva SE.